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There is no agreement on the minimum absolute eosinophil count essential for the diagnosis of tropical pulmonary 
eosinophilia (TPE) at present. The aim of this study was to determine this figure as well as to evaluate the other 
diagnostic criteria of TPE. 
The response to diethylcarbamazine (DEC) was tested in 98 patients [of whom 79 (80.6%) completed the study] 
by means of clinical scores, lung function tests and the absolute eosinophil counts. 
The minimum absolute eosinophil count necessary for the diagnosis of TPE was found to be 3300 for two 
reasons. Firstly there was a marked fluctuation in the mean percentage change of the absolute eosinophil count 
after treatment with DEC, when it was below 3225 cells mmh3, while the mean percentage reduction showed a 
remarkable stability when the eosinophil count exceeded 3600. Secondly there was a marked difference in the 
response to DEC in patients whose eosinophil counts were above and below these values. 
All patients who had eosinophil counts greater than 3600 responded to DEC and were diagnosed as cases of 
TPE. All of them were from filarial endemic areas. The total eosinophil count decreased by a mean of 92.5%, 3 
months after administration of DEC. 
The sensitivities of the following tests in TPE were as follows: filarial antibody test (FAT) 30%, radiological 
changes 45*5%, erythrocyte sedimentation rate (ESR) 80%. The radiological changes and the ESR, but not the 
FAT, were helpful in differentiating TPE from those patients with TPE-like symptoms but with lower eosinophil 
counts, e.g. those with asthma. 
Patients with cough who had eosinophil counts of between 53 and 2000 cells mm-‘, showed elevated filarial 
antibody levels in a significant number of cases when compared to asymptomatic subjects. (P < 0.00 1). Five of them 
responded to DEC. Three of these had filarial antibody in their serum and one had bilateral mottling on chest X- 
ray. These results suggest that atypical cases of TPE may exist. 
Our study has shown that the diagnosis of TPE rests on the following criteria: cough worse at night; residence in 
a filarial endemic area; the eosinophil count greater than 3300 cells mm-3, clinical and haematological response to 
DEC. The diagnosis is supported by radiological changes and elevated ESR. The FAT is of little value. 
The clinical benefit and the improvement in lung function which follows the administration of DEC was 
sustained up to a minimum period of 15 months. 
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Introduction 
Tropical pulmonary eosinophilia is one of the many 
syndromes with pulmonary infiltrates and peripheral blood 
eosinophilia (PIE). It is an interstitial lung disease thought 
to result from immunological hyperresponsiveness to the 
human lymphatic dwelling filarial parasites Wuchereria 
bancrofti and Brugia malayi (1) although other non-filarial 
helminth-induced PIES resembling tropical pulmonary 
eosinophilia have been described recently (2). Beaver 
proposed the following criteria for the diagnosis of tropical 
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pulmonary eosinophilia (TPE); eosinophilia over 2000 
mme3, cough/breathlessness at night, radiological evidence 
of lung striations/mottling at bases, elevated erythrocyte 
sedimentation rate, a high titre of complement fixation and 
a cure with arsenic or diethylcarbamazine (DEC) (3). 
Donohugh suggested four major criteria, or three major 
and three minor criteria, for the diagnosis of this condition 
(4). The major criteria are cough and dyspnoea which are 
worse at night, an eosinophil count of over 2000 cells 
mm-‘, a positive filarial complement fixation test and a 
clinical and haematological response to DEC. The minor 
criteria are residence in an endemic filarial area for several 
months, presence of the illness in a young adult male, 
expiratory rhonchi with inspiratory crepitations, chest film 
showing diffuse mottling along with increased hilar and 
basal markings, elevated erythrocyte sedimentation rate 
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and accompanying non-specific symptoms such as malaise, 
fatigue, anorexia and weight loss. 
The detection of filarial antibodies by the complement 
fixation test, which is obsolete, has been replaced by the 
indirect immunofluorescent test (FAT) (5), while many 
minor criteria are non-specific. 
There is no agreement on the minimum absolute 
eosinophil count necessary for diagnosis of TPE. Some 
authors specify a minimum of 2000 eosinophils mmp3, 
(3,4,6) while others refer to a count of 3000 eosinophils 
mme3 (7,8,9). We have observed patients who have 
symptoms consistent with TPE and show circulating filarial 
antibodies but with normal or slightly raised eosinophil 
counts, who respond to DEC. Thus atypical cases of TPE 
probably exist. It is therefore necessary to determine the 
therapeutic response of DEC in relation to the degree of 
eosinophilia and to re-examine the diagnostic criteria of 
TPE. 
Patients and Methods 
The study population consisted of 98 patients of both sexes 
between the ages of 12 and 74 years (mean 31 years). All of 
them had cough and an eosinophil count ranging from 53 
to 49 840 cells per mm3. They were referred to one of the 
authors (J.H.L.C.) from the outpatients department, Chest 
Hospital, Welisara, Sri Lanka. All except three were from 
filarial endemic areas. All patients were given DEC 150 mg 
three times a day for 10 days. 
The following patients were excluded from the study: 
children under 12 years of age; patients with cough or 
dyspnoea of less than 2 weeks duration; those who had 
taken DEC during the previous year or were on steroid 
therapy; patients with past or present pulmonary tubercu- 
losis or with chronic lung disease; chronic alcoholics; 
patients with chronic renal disease; or those with abnorm- 
alities of the central nervous system. 
A detailed history was obtained from each patient and a 
clinical examination was carried out at the onset as well as 
on each follow-up visit. Clinical symptoms were graded and 
given the following scores: 1. absence of symptoms; 2. able 
to carry out normal work or having undisturbed sleep in 
spite of symptoms; 3. symptoms interfering with normal 
work or sleep; 4. complete incapacitation (unable to get out 
of bed). The mean of all post-treatment clinical scores, 
TABLE 1. Schedule of investigations during follow-up 
forced vital capacity (FVC) and absolute eosinophil counts 
observed during follow-up were recorded as the mean post- 
treatment clinical score, mean FVC and mean eosinophil 
count, respectively, in each patient.The deviation from the 
pre-treatment values was calculated for these three para- 
meters. 
The following lung function tests were carried out at the 
time of each clinical examination: peak expiratory flow rate 
(PEFR); forced expiratory volume in 1s (FEVi); and forced 
vital capacity (FVC). The FEVi/FVC ratio was calculated 
in each case. Other investigations carried out were chest X- 
ray; white blood cell and differential count; erythrocyte 
sedimentation rate (ESR); indirect immunofluorescent 
assay for filarial antibodies (FAT) (using Wuchereria 
bancrofti antigen) (5); direct smear and culture for fungi 
in sputum; and detection of antibodies against Aspergillus 
jiimigatus, Histoplasma capsulatum, Blastomyces dermatiti- 
dis, Coccidiodes immitis and Candida albicans in serum. 
All patients were followed up-at the end of 1,3,6,9,12 and 
15 months and investigations were carried out according to 
the schedule outlined in Table 1. 
The ESR was considered raised if it was over 14 mm in 
the first hour in men and over 20 mm in women (10). To 
assess the presence of filarial antibodies in asymptomatic 
individuals living in the same localities, tests were carried 
out on serum samples of 51 such individuals. 
The response to DEC was considered satisfactory if two 
or more of the following parameters were fulfilled: mean 
percentage reduction in the absolute eosinophil count of 
more than 70% (Fig. 1) increase in FVC of more than lo%, 
reduction in the mean clinical score of more than 40%. 
STATISTICAL ANALYSIS 
The SND test (Z-test) was used to compare the sensitivity 
of the FAT, radiological changes and elevated ESR 
between patients with TPE and other groups as well as to 
examine the relationship between a raised ESR and 
radiological abnormalities in TPE. The Student’s t-test 
was used to assess the response of patients to DEC, 
(reduction in clinical score, increase in FVC, reduction in 
eosinophil count in relation to the pre-treatment eosinophil 
count) as well as to assess the mean clinical scores and FVC 
of the patients with TPE at different periods following 
treatment with DEC. 
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FIG. 1. Changes in the eosinophil count after DEC. *Not all pre-treatment eosinophil counts are indicated numerically. 
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Results 
All 98 patients had cough, which was nocturnal in 90 
(91.8%) while 78 (81.1%) had wheezing and 84 (85.7%) 
had shortness of breath. The absolute eosinophil counts of 
the 79 (80.6%) who completed the study ranged from 53 to 
49 840 cells mm-’ (mean 10 635.6). Of these 79 patients, 21 
had an eosinophil count of less than 2000. Five of the 21 
responded to DEC, three of them showed filarial antibodies 
and one had radiological evidence of mottling. 
The laboratory findings in patients were classified 
according to their eosinophil counts: less than 2000 (group 
A); 2001-3500 (group B); > 3500 (group C); and 
asymptomatic subjects (group D), as indicated in Table 2. 
The positivity of the FAT in patients with TPE (group C) as 
well as in patients in group A was significantly greater when 
compared to asymptomatic subjects. (group D) (P<O.Ol 
and 0.001, respectively) but did not show a significant 
difference between groups A and C. On the other hand, the 
ESR was significantly greater in patients in group C when 
compared to patients in groups A (P<O.OOl) and B 
(P < 0.05). Radiological abnormalities were significantly 
greater in patients in group C compared to group A 
@<O-05) but not group B (P= 0.43). Of the patients with 
TPE who showed radiological abnormalities, 94.4 % had a 
raised ESR, which was a significant correlation (PcO.05). 
Forty-five of the 51 cases of TPE were examined for 
evidence of fungal infection. On direct smear, Candida 
albicans was detected in the sputum in five cases and on 
culture in three cases. However, the serological tests for 
fungal antibodies were negative in all cases. 
Patients in groups A and B showed statistically equivalent 
responses to DEC with regard to the three parameters used 
to assess the response to DEC, namely a mean percentage 
TABLE 2. Laboratory findings in different groups of patients and asymptomatic subjects 
Group Patient category FAT positive Chest X-ray changes? 
n/total (%) n/total (%) 
Elevated ESR 
n/total (%) 
A Patients with absolute eosinophil counts be- 8/21*** l/l1 (9.1%) 
tween 0 and 2000 cells mm-’ (probable 
6/16(37.5%) 
(38.1%) 
asthmatics/atypical cases of TPE) 
B Patients with absolute eosinophil counts be- l/6(16-6%) l/4 (25%) 
tween 2001 and 3500 cells mm-’ 
2/5 (40%) 
C Patients with eosinophil counts of over 3500 15/50*** 
cells mm-a (TPE) 
20/44* (45.5%) 40/50*, ** 
(30%) (80%) 
D Asymptomatic subjects 4/51 (7.8%) ND ND 
+Increased vascular markings, multiple nodules/mottling. 
ND, Not done. 
Significance (P<O*O5):* group C vs. group A;. ** group C vs. group B; *** groups C/A vs. group D. 
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reduction in the eosinophil count, reduction in the mean 
clinical score and increase in FVC respectively. On the other 
hand, the response to DEC of patients in groups A and B 
was significantly different to that of group C with regard to 
the mean percentage reduction in eosinophil count, and the 
reduction in the mean clinical score. Although there was an 
increase in FVC, this did not appear to be significant 
(Table 3). 
All 51 patients who had eosinophil counts over 3500 
responded to DEC. They all showed a mean percentage 
reduction of the eosinophil count of over 70%; 48 
(94.1%) showed a reduction of the mean clinical score 
of over 40% and 39 (76.5%) had an increase in FVC 
of over 10%. Therefore, these 51 cases were diagnosed as 
cases of TPE. All of them were from the filarial endemic 
areas of Sri Lanka. They included 42 men (82.4%) and 
nine women (17.6%). Their ages varied from 12 to 74 
years, with a mean of 33.4 years. In this group of patients, 
50 (98%) had nocturnal cough and 11 (21%) gave a 
history of fever, while a family history of asthma was 
present in 41.2% of cases. The lung signs included 
rhonchii in 70% and rhonchii and crepitations in 22%, 
while the lungs were clear in 8%. The absolute eosinophil 
counts ranged from 3600e3 to 49 840 mmM3 (mean, 15 
582.2; SD, 11 258.4). Lung function tests in patients with 
TPE showed a restrictive defect in 76% and an 
obstructive pattern in 24%. There was a relatively 
uniform reduction in the absolute eosinophil count, after 
administration of DEC, when the eosinophil count 
exceeded 3600 mm-‘. When the eosinophil count was 
less than 3225 cells mmp3, there was a marked fluctuation 
of the mean percentage change in the count (Fig. 1). The 
total eosinophil count decreased by 92.5%, 3 months 
after administration of DEC. 
The mean of the clinical scores of all the patients with 
TPE was significantly reduced (P<O*OOl), while the mean 
of the FVC values was significantly increased (P<O.OOl) 
after treatment with DEC throughout the entire follow-up 
period of 15 months. 
TABLE 3. Response to DEC 
Discussion 
Some of the features recorded in our study confirmed 
observations made by previous investigators. Of the cases 
of TPE, 82.4% were men (7,9). Lung function tests showed 
an obstructive pattern in 24% of cases, as has been shown 
previously (12). A positive filarial antibody test was 
observed in 30% of our patients, which is similar to the 
rate of 33.3% shown by De Sylva et al. (13). Increased 
vascular markings and/or multiple nodules or mottling in 
chest X-rays were seen in 45.5% of patients with TPE. 
These changes were observed by Jayewardene et al. (14) in 
64% of their patients. Our results have shown that the 
radiological changes and the ESR, but not the FAT, are 
helpful in differentiating TPE patients from those with 
TPE-like symptoms but with lower eosinophil counts, such 
as in asthma. An elevated ESR and changes in the chest X- 
ray were shown to be correlated, therefore including them 
as two different criteria may lead to over-diagnosis. 
The mean clinical scores and lung function (FVC) were 
maintained up to the end of the study (15 months after 
administration of DEC), suggesting that the drug is 
effective for this period. 
Patients in group A showed elevated filarial antibodies in 
a significant number of cases when compared to asympto- 
matic subjects (P<O.OOl). Five of them responded to DEC. 
These included three who had filarial antibodies in their 
serum and one who had radiological evidence of mottling in 
both lung fields. These could be either atypical cases of TPE 
or asthma precipitated by filariasis (13). The fact that 21 
out of 51 (41.2%) of our patients with TPE had a family 
history of asthma suggests that those who have a 
predisposition to be asthmatic and probably have airway 
hyperresponsiveness are more likely to develop TPE. Thus, 
there appears to be a close link between these two diseases. 
None of the patients in our group had evidence of 
cryptogenic pulmonary eosinophilia (15). Candida albicans 
was isolated on direct smear or culture in seven patients 
with TPE, but a fungal aetiology was excluded by the fact 
Group Absolute E C F FAT positive N 
eosinophil count n/total (%) 
O/3 l/3 213 313 
A < 2,000 -75.31 - 36.37 20.43 S/21 (38.1%) 5121 11/21 3121 2121 
(n=21) 
B 2,001-3,500 -48.15 -40.83 8.35 l/6 (16.6%) 217 317 217 Oil 
:=7’ > 3,500 -g1.19*,** -59.53*,** 36.37 15/50 (30%) o/51 o/51 16151 35/51**** 
(n=.51) 
E, Mean percentage reduction of the absolute eosinophil count after DEC 
C, Mean percentage reduction of the clinical score after DEC 
F, Mean percentage increase in the FVC after DEC 
N, Number of parameters that have responded to DEC. 
Significance (PcO.05): * group C vs. group A; ** group C vs. group B. 
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that serum samples of these patients did not show 
antibodies to Candida albicans, suggesting that when this 
organism was present in the sputum, it was probably a 
contaminant. 
Our study unfortunately did not include any patients 
with eosinophil counts between 3225 and 3660 cells mmp3, 
thus the cut-off point probably lies between these two 
values. There is clear evidence that the minimal eosinophil 
count for the diagnosis of TPE should be 3300 cells mm-‘. 
This is based on two criteria. Firstly, patients who had 
eosinophil counts between 2000 and 3225 cells mm-’ 
showed a response to DEC which was similar to those with 
eosinophil counts below 2000 cells mm-‘, while a different 
response was elicited in patients whose eosinophil counts 
exceeded 3500 cells mmM3. Secondly, the mean percentage 
reduction of the absolute eosinophil count showed a 
remarkable stability when the eosinophil count exceeded 
3600 cells mm-‘. 
The cut-off point in the eosinophil count to distinguish 
between asthma and TPE is particularly important as 
studies have shown that there is a significant correlation 
between the peripheral blood eosinophil count and clinical 
severity as well as with the risk of mortality in asthma 
(16,17). Misdiagnosis of an asthmatic with a high periph- 
eral eosinophil count as a case of TPE could therefore have 
serious consequences. 
Our study has shown that the diagnosis of TPE rests on 
the following criteria: cough worse at night; residence in a 
filarial endemic area; eosinophil count greater than 3300 
cells mmp3; and clinical and haematological response to 
DEC. The diagnosis is supported by radiological changes 
and elevated ESR. The FAT is of little value. 
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